Rescheduling meets pricing pressure: US cannabis operators report Q1 2026 results
[#item_full_content] The first quarter of 2026 arrived with a federal tailwind, medical cannabis rescheduled to Schedule III under the Controlled Substances Act, but the underlying economics of state-licensed… Read More